

**From:** [Jacqueline Zeledon](#)  
**To:** [AGO - High Cost Prescription Drugs](#)  
**Subject:** Re: Prescription Drug Manufacturers and SB 216 (Act 165)/SB 92 (Act 193)  
**Date:** Wednesday, May 8, 2024 12:10:03 PM

---

**EXTERNAL SENDER: Do not open attachments or click on links unless you recognize and trust the sender.**

Good morning,

Could you please take a look at our question in the email (below)? We really appreciate your help.

Thank you very much,

Best regards,  
Jacqueline Zeledon

888-730-0730 ext. 22  
[jzeledon@classoneinsight.com](mailto:jzeledon@classoneinsight.com)

Manager, State Price Transparency Reporting (SPTR), Research and Processes

ClassOne Insight, Inc.  
ClassOneInsight.com

On Thu, May 2, 2024 at 5:22 PM Jacqueline Zeledon <[jzeledon@classoneinsight.com](mailto:jzeledon@classoneinsight.com)> wrote:

Good afternoon,

Could you please help us with a question regarding Vermont's SB 216 (Act 165) and SB 92 (Act 193) and prescription drug manufacturers?

- When your team is evaluating price increase thresholds for a product that was recently acquired by the current manufacturer, are you evaluating the current price increase thresholds based on prices by the current manufacturer or are you considering prices that may precede the acquisition?

Thank you very much for your time and any information. We really appreciate your help.

Best regards,  
Jacqueline Zeledon

888-730-0730 ext. 22  
[jzeledon@classoneinsight.com](mailto:jzeledon@classoneinsight.com)  
Manager, State Price Transparency Reporting (SPTR), Research and Processes  
ClassOne Insight, Inc.  
ClassOneInsight.com